NASDAQ$AKRO
Akero Therapeutics Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Akero Therapeutics reported financial results for the third quarter of 2021.
Akero Therapeutics reported third quarter financial results with focus on advancing efruxifermin (EFX) through Phase 2b clinical trials for NASH treatment.
- Focused on completing two Phase 2b clinical trials.
- Diligently working with regulators to bring efruxifermin (EFX) to market.
- Received Fast Track designation from the FDA.
- EFX is being evaluated in the HARMONY and SYMMETRY studies.
Headline financials
Revenue & EPS history
Akero · Revenue · Quarterly
$0
Forward guidance
Forward-looking statements involve risks and uncertainties, and actual results may differ materially.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
-0.4%
Avg return
Earnings day
-1.8%
Avg return
5 days after
+1.5%
Avg return
30 days after
54%
14 / 26 earnings
Positive
+18.4%
Q2 2022
Best reaction
-20.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.2% | +0.3% | +0.9% | |
| Q2 2025 | +0.1% | -4.2% | -11.3% | |
| Q1 2025 | +4.3% | -2.5% | +33.0% | |
| Q4 2024 | +2.9% | -5.4% | -8.8% | |
| Q3 2024 | -5.2% | -11.2% | -10.8% | |
| Q2 2024 | -3.0% | -4.2% | +6.2% | |
| Q1 2024 | -0.9% | +1.2% | +10.5% | |
| Q4 2023 | +2.1% | +12.0% | -7.3% | |
| Q3 2023 | +5.3% | — | — | |
| Q2 2023 | +6.2% | — | — | |
| Q1 2023 | +0.2% | — | — | |
| Q4 2022 | -4.1% | — | — | |
| Q3 2022 | -6.8% | — | — | |
| Q2 2022 | +18.4% | — | — | |
| Q1 2022 | -11.4% | — | — | |
| Q4 2021 | -1.9% | — | — | |
| Q3 2021 | +4.6% | — | — | |
| Q2 2021 | +1.0% | — | — | |
| Q1 2021 | +2.6% | — | — | |
| Q4 2020 | -1.1% | — | — | |
| Q3 2020 | -3.0% | — | — | |
| Q2 2020 | -0.9% | — | — | |
| Q1 2020 | +2.8% | — | — | |
| Q4 2019 | -20.9% | — | — | |
| Q3 2019 | -3.8% | — | — | |
| Q2 2019 | +1.3% | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro